CD274 and colorectal carcinoma: This dual actions of tumoricidal activity and immune stimulation may exert a synergistic therapeutic effect when used in conjunction with anti-PD-1/PD-L1 immune checkpoint inhibitors, potentially overcoming primary resistance to immunotherapy in MSS CRC patients.